SOLIGENIX, INC.
SNGX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SNGX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SNGX
Soligenix, Inc. is a late-stage biopharmaceutical company developing and commercializing products for rare diseases with unmet medical needs, focusing on photodynamic therapy for cutaneous T-cell lymphoma and expanding into psoriasis.
Key risk: Nasdaq delisting risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 4 clinical trials for SOLIGENIX, INC..
Soligenix, Inc. is a late-stage biopharmaceutical company developing and commercializing products for rare diseases with unmet medical needs, focusing on photodynamic therapy for cutaneous T-cell lymphoma and expanding into psoriasis.
- Soligenix is a late-stage biopharmaceutical company focused on rare diseases with unmet medical needs, with two active business segments: Specialized BioTherapeutics and Public Health Solutions [sec_mda · as of 2025-03-21].
- The company's lead product candidate, HyBryte™ (SGX301 or synthetic hypericin sodium), is a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL) that has completed a Phase 3 FLASH trial [sec_mda · as of 2025-03-21].
- Soligenix is expanding development of synthetic hypericin under the research name SGX302 into psoriasis, with plans for a Phase 2a clinical trial following positive proof-of-concept in a small Phase 1/2 pilot study [sec_mda · as of 2026-08-07].
- As of June 30, 2025, the company had cash and cash equivalents of $5,097,670, a decrease from $7,819,514 at December 31, 2024, primarily due to operating activities and debt repayment [sec_mda · as of 2025-08-14].
- The company is pursuing business development opportunities for pipeline programs and exploring all strategic alternatives, including merger/acquisition strategies [sec_mda · as of 2026-08-07].
What works
- Soligenix has a late-stage product candidate, HyBryte™, for cutaneous T-cell lymphoma (CTCL) that has completed a Phase 3 trial, indicating progress toward potential commercialization [sec_mda · as of 2025-03-21].
- The company is expanding its pipeline into psoriasis with SGX302, leveraging positive proof-of-concept data from a Phase 1/2 pilot study, which could open additional market opportunities [sec_mda · as of 2026-08-07].
- Soligenix is actively pursuing business development and strategic alternatives, including merger/acquisition strategies, to enhance its pipeline and financial position [sec_mda · as of 2026-08-07].
What to weigh
- The company faces significant uncertainty in obtaining future financing, as it may need additional funds to support operations and clinical trials [sec_mda · as of 2026-08-07].
- Soligenix has a risk of non-compliance with Nasdaq's minimum bid price requirement, which could lead to delisting and adversely affect stock liquidity [sec · filed 2026-06-12].
- The company's cash and cash equivalents decreased from $7.8 million to $5.1 million in the first half of 2025, indicating a cash burn that may require near-term capital raises [sec_mda · as of 2025-08-14].
- There is inherent uncertainty in whether product candidates will be sufficiently safe and effective to support regulatory approvals, which could delay or prevent commercialization [sec_mda · as of 2026-08-07].
From the filings
Quoted directly from source documents.
Soligenix is a late-stage biopharmaceutical company focused on rare diseases with unmet medical needs.
“We are a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.”
SEC MD&A · March 21, 2025
The company is exploring strategic alternatives including merger/acquisition.
“Pursue business development opportunities for pipeline programs, as well as explore all strategic alternatives, including but not limited to merger/acquisition strategies.”
SEC MD&A · August 7, 2026
Soligenix has a risk of Nasdaq delisting due to bid price non-compliance.
“the Company's ability to regain compliance with the Nasdaq Listing Rule 5550(a)(2) minimum bid price requirement within the applicable compliance period, the potential delisting of the Company's common stock from The Nasdaq Capital Market”
SEC filings · June 12, 2026
Risks & what to watch (4)›
Key risks
- Nasdaq delisting risk — Potential delisting if minimum bid price compliance is not regained, affecting stock liquidity [sec · filed 2026-06-12].
- Financing uncertainty — Need for future financing to support operations and trials, with no guarantee of availability [sec_mda · as of 2026-08-07].
- Clinical and regulatory risk — Uncertainty whether product candidates will be safe and effective enough for regulatory approval [sec_mda · as of 2026-08-07].
- Cash burn and limited runway — Cash decreased to $5.1M as of June 30, 2025, with ongoing operating losses [sec_mda · as of 2025-08-14].
What to watch
- Progress of the Phase 2a clinical trial for SGX302 in psoriasis, following positive proof-of-concept [sec_mda · as of 2026-08-07].
- Ability to regain compliance with Nasdaq's minimum bid price requirement and avoid delisting [sec · filed 2026-06-12].
- Outcome of business development and strategic alternative evaluations, including potential merger/acquisition [sec_mda · as of 2026-08-07].
- Future financing activities and cash runway updates, given the decreasing cash position [sec_mda · as of 2025-08-14].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run SOLIGENIX, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SOLIGENIX, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
17.4 months
D/E 0.58 · 0% dilution
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
11
Total value held
$373K
| Holder | Shares | Value |
|---|---|---|
| geode capital management, llc | 120,267 | $142K |
| vanguard capital management llc | 116,800 | $138K |
| vanguard fiduciary trust co | 53,914 | $64K |
| xtx topco ltd | 20,799 | $25K |
| morgan stanley | 3,592 | $4K |
| plante moran financial advisors, llc | 209 | $247 |
| jones financial companies lllp | 100 | $113 |
| citigroup inc | 19 | $22 |
| cwm, llc | 6 | $7 |
| osaic holdings, inc. | 2 | $2 |
Showing top 10 of 11 institutional holders of SOLIGENIX, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 7.9%
- Days to cover
- 2.5
- Shares short
- 809,139
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SNGX short interestGovernance
Frequently asked questions
What is the AI investment thesis for SOLIGENIX, INC.?
Soligenix, Inc. is a late-stage biopharmaceutical company developing and commercializing products for rare diseases with unmet medical needs, focusing on photodynamic therapy for cutaneous T-cell lymphoma and expanding into psoriasis.
What is SOLIGENIX, INC.'s lead drug candidate?
SOLIGENIX, INC.'s most advanced tracked candidate is dusquetide (Phase 2) for Behçet Disease.
Who is the CEO of SOLIGENIX, INC.?
Dr. Christopher J. Schaber Ph.D. is the chief executive officer of SOLIGENIX, INC. (SNGX).
Where is SOLIGENIX, INC. headquartered?
SOLIGENIX, INC. (SNGX) is headquartered in Princeton, NJ, United States.
What therapeutic areas does SOLIGENIX, INC. focus on?
SOLIGENIX, INC. develops therapies across Oncology, Immunology, Infectious Disease, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.